middle.news
Mesoblast Secures 7-Year FDA Orphan-Drug Exclusivity for Ryoncil in Pediatric SR-aGvHD
2:27am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Mesoblast Secures 7-Year FDA Orphan-Drug Exclusivity for Ryoncil in Pediatric SR-aGvHD
2:27am on Monday 2nd of June, 2025 AEST
Key Points
Seven years of FDA orphan-drug exclusivity for Ryoncil in pediatric SR-aGvHD
Biologic exclusivity extends market protection until December 2036
Robust intellectual property portfolio securing commercial rights through 2044
Ryoncil is the first FDA-approved mesenchymal stromal cell therapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MESOBLAST (ASX:MSB)
OPEN ARTICLE